文献速递艾滋病与性传播感染病毒性肝炎

生长激素释放激素可降低HIV合并NAFLD患者的循环免疫激活标志物并与肝脏免疫通路效应平行

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该双盲随机试验在61例HIV感染合并非酒精性脂肪性肝病(NAFLD)患者中比较替莫瑞林与安慰剂12个月的效果。替莫瑞林显著降低13种循环蛋白(包括趋化因子、细胞因子和T细胞相关分子),无蛋白升高,肝脏转录组证实免疫激活通路下调。提示增强生长激素轴可能改善HIV代谢紊乱患者的免疫激活。

要点

  • 替莫瑞林治疗12个月降低HIV合并NAFLD患者循环中13种免疫激活相关蛋白。
  • 降低的蛋白涉及细胞毒性T细胞和单核细胞活化,肝组织转录组证实免疫通路下调。
  • 增强生长激素轴可能成为减轻HIV患者系统性及终末器官免疫激活的策略。

核心结论

  • 长期使用GHRH类似物替莫瑞林可降低HIV合并NAFLD患者的T细胞和单核/巨噬细胞活化标志物。

研究设计与样本

  • 双盲随机对照试验,纳入61例HIV合并NAFLD患者,替莫瑞林与安慰剂对比12个月,检测血浆92种免疫/趋化/代谢生物标志物并行肝活检基因集富集分析。

主要发现

  • 替莫瑞林组较安慰剂组显著降低13种循环蛋白,无蛋白升高。
  • 降低的蛋白包括4种趋化因子(CCL3、CCL4、CCL13、IL8)、2种细胞因子(IL-10、CSF-1)、4种T细胞相关分子(CD8A、CRTAM、GZMA、ADGRG1)以及ARG1、Gal-9和HGF。
  • 网络分析显示这些蛋白相关基因通路密切相互作用,插补分析提示一组免疫通路下调。
  • 肝组织靶向转录组证实免疫激活通路显著下调的终末器官信号。

临床怎么用

  • 对于HIV合并NAFLD且代谢紊乱、存在系统性炎症的患者,GHRH类似物可能有助于减轻免疫激活,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modulates critical metabolic pathways; however, little is known regarding effects of augmenting pulsatile GH secretion on immune function in humans. This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and liver tissue in people with human immunodeficiency virus (HIV) (PWH) and nonalcoholic fatty liver disease (NAFLD). METHODS: 92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months. Gene set enrichment analysis was performed on serial liver biopsies targeted to immune pathways. RESULTS: Tesamorelin, compared to placebo, decreased interconnected proteins related to cytotoxic T-cell and monocyte activation. Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin. These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF. Network analysis indicated close interaction among the gene pathways responsible for these proteins, with imputational analyses suggesting down-regulation of a closely related cluster of immune pathways. Targeted transcriptomics using liver tissue confirmed a significant end-organ signal of down-regulated immune activation pathways. CONCLUSIONS: Long-term treatment with a GHRH analog reduced markers of T-cell and monocyte/macrophage activity, suggesting that augmentation of the GH axis may ameliorate immune activation in an HIV population with metabolic dysregulation, systemic and end organ inflammation. Clinical Trials Registration. NCT02196831.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Stanley TL, Fourman LT, Wong LP, et al. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021. PMID: 33852720. doi:10.1093/cid/ciab019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。